Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (181-190 of 339) with videos related to

Pageof 34
Sort By:
Leukemia Research|May 14, 2021
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral centerKathrin Nachtkamp, Josefine Stark, Andrea Kündgen, et al.
Blood|July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromesAzim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Cancers|June 19, 2024
Overlapping Stromal Alterations in Myeloid and Lymphoid NeoplasmsLucienne Bogun, Annemarie Koch, Bo Scherer, et al.
Leukemia Research|January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromesJudith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)Uwe Platzbecker, Martin Bornhäuser, Ulrich Germing, et al.
Haematologica|August 10, 2012
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcomeBarbara Deschler, Gabriele Ihorst, Uwe Platzbecker, et al.
Cancers|February 10, 2024
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid MalignanciesFelicitas Schulz, Paul Jäger, Johanna Tischer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2012
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidineUwe Platzbecker, Johannes Schetelig, Jürgen Finke, et al.
Experimental Hematology|November 9, 2002
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioningGuido Kobbe, Peter Schneider, Manuel Aivado, et al.
Ejhaem|March 5, 2025
Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors-A Single Center Experience in 152 PatientsPaul Jäger, Benno Biermann, Nora Liebers, et al.
Pageof 34

Showing results (181-190 of 339) with videos related to

Sort By:
Pageof 34
Leukemia Research|May 14, 2021
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral centerKathrin Nachtkamp, Josefine Stark, Andrea Kündgen, et al.
Blood|July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromesAzim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Cancers|June 19, 2024
Overlapping Stromal Alterations in Myeloid and Lymphoid NeoplasmsLucienne Bogun, Annemarie Koch, Bo Scherer, et al.
Leukemia Research|January 4, 2019
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromesJudith Neukirchen-Strapatsas, Heinz Tuechler, Matteo Della Porta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)Uwe Platzbecker, Martin Bornhäuser, Ulrich Germing, et al.
Haematologica|August 10, 2012
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcomeBarbara Deschler, Gabriele Ihorst, Uwe Platzbecker, et al.
Cancers|February 10, 2024
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid MalignanciesFelicitas Schulz, Paul Jäger, Johanna Tischer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2012
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidineUwe Platzbecker, Johannes Schetelig, Jürgen Finke, et al.
Experimental Hematology|November 9, 2002
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioningGuido Kobbe, Peter Schneider, Manuel Aivado, et al.
Ejhaem|March 5, 2025
Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors-A Single Center Experience in 152 PatientsPaul Jäger, Benno Biermann, Nora Liebers, et al.
Pageof 34